Is AbCellera Biologics (ABCL) Undervalued After New ABCL635 Data Presentation Plans?

AbCellera Biologics (ABCL) is drawing attention after announcing plans to present new Phase 1/2 data for its lead antibody ABCL635 at The Menopause Society's 2026 Annual Meeting.

The latest move in AbCellera Biologics comes after a sharp year to date share price return of 265.74% and a very strong 90 day share price gain of 84.49%. This occurred even though the 7 day share price return fell 8.70%, which points to strong longer term momentum with some short term profit taking as investors react to fresh ABCL635 data and the shift toward a clinical stage model.

See how AbCellera Biologics fits into a broader pipeline shift by reviewing a hand-picked set of 34 healthcare AI stocks that are also focusing on data-driven drug discovery and development.

After a move like this, and with AbCellera Biologics now firmly priced as a clinical story rather than just a platform, does the current valuation still leave enough potential upside to justify the risk you are taking on?

Most Popular Narrative: 27% Undervalued

AbCellera Biologics last closed at $12.55, while the most followed narrative pegs fair value closer to $17.13. This frames the recent rally as only part of the move analysts think is needed to fully reflect the pipeline and partnership story.

The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the resources to support long-term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.

See why 61 investors see AbCellera Biologics as 27% undervalued.

Result: Fair Value of $17.13 (UNDERVALUED)

Still, the story can break if ABCL635 underwhelms in longer term data or if heavy R&D spending continues to widen AbCellera Biologics' losses.

Find out about the key risks to this AbCellera Biologics narrative.

Another Lens On AbCellera Biologics: What The Multiples Say

On the first take, AbCellera Biologics looks mispriced against a $17.13 fair value narrative. On a simple P/B lens, the picture is more complicated. The stock trades around 4.5x book, richer than the US Life Sciences sector at 3.4x, yet well below a 11.5x peer average. That gap can signal either room for rerating or a warning that peers are pricing in far more success than this business currently justifies. Which side of that spread do you think the market is likely to close toward next?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around AbCellera Biologics is split, which is exactly why the data matters more than the headlines. Act while the story is still forming and weigh both sides of the case by checking the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond AbCellera Biologics?

If AbCellera Biologics has your attention, do not stop here. Broader context from other high quality opportunities can sharpen your next move.

• Target potential mispricing by scanning a curated pool of companies that combine quality fundamentals with appealing entry points through the 28 high quality undervalued stocks.
• Prioritise resilience and sleep-better-at-night holdings by checking a 31 resilient stocks with low risk scores that filters for businesses with sturdier profiles.
• Unearth underfollowed opportunities by reviewing a 20 high quality undiscovered gems that surfaces lesser known stocks with solid financial underpinnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com